
Opinion|Videos|July 12, 2024
Evaluating Value of BTK Inhibitors in CLL Treatment
Experts evaluate the value of BTK inhibitors in CLL treatment.
Advertisement
Episodes in this series

Video content above is prompted by the following question(s):
- How are payers evaluating the value of BTK inhibitors in the evolving treatment landscape of CLL?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Most Favored Nation Drug Pricing Moves Forward, but Experts Warn Details Are Still Missing
2
Medicaid Work Requirements Set to Leave Millions Without Insurance
3
Oncology Landscape Continues to Evolve With Expanded Indications, First-in-Class Therapies
4
Timely Outpatient Follow-Up Reduces Hospital Readmissions
5















































